1
|
Acevedo A, Muñoz KA, Stec M, Pitt K, Jones SA, Manfredi JM. Effect of preoperative ondansetron on postoperative nausea in healthy dogs undergoing laparoscopic gastropexy and castration. Vet Anaesth Analg 2024; 51:235-243. [PMID: 38413340 DOI: 10.1016/j.vaa.2024.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 01/22/2024] [Accepted: 01/25/2024] [Indexed: 02/29/2024]
Abstract
OBJECTIVE To investigate if preoperative ondansetron reduces postoperative nausea associated with laparoscopic gastropexy and castration in dogs. STUDY DESIGN Prospective clinical study. ANIMALS Twenty client-owned, healthy male dogs. METHODS Dogs were premedicated with dexmedetomidine (2-5 mcg kg-1) and methadone (0.2-0.5 mg kg-1) intramuscularly. General anesthesia was induced with propofol and maintained with an inhalant anesthetic agent. Dogs were randomized into group S (saline 0.1 mL kg-1, intravenously) or group O (ondansetron 0.2 mg kg-1, intravenously). Plasma and serum were collected before premedication and 3 hours postextubation to measure arginine vasopressin (AVP) and cortisol concentrations. Nausea scoring occurred before and 10 minutes after premedication, immediately after extubation, and at 1, 2 and 3 hours postextubation. Data were analyzed by mixed and split-plot anova with Bonferroni adjustment for the number of group comparisons. Significance was set at p < 0.05. RESULTS Nausea scores increased over time at 1 (p = 0.01) and 2 (p < 0.001) hours postextubation in both groups compared with before premedication. Median nausea score (0-100 mm) for groups S and O before premedication were 2.5 and 0.5 mm, respectively. At 1 and 2 hours postextubation, group S scored 7.5 and 4.0 mm and group O scored 6.0 and 5.0 mm, respectively. No significant differences in nausea scores within or between groups were observed before premedication and 3 hours postextubation. Cortisol concentrations increased significantly 3 hours postextubation in both groups (p < 0.001) compared with before premedication, with no differences between groups. AVP concentrations showed no significant differences within or between groups. CONCLUSIONS AND CLINICAL RELEVANCE Preoperative intravenous administration of ondansetron (0.2 mg kg-1) did not impact postoperative nausea after laparoscopic gastropexy and castration. Investigation of higher doses of ondansetron on the incidence of postoperative nausea and vomiting in dogs after surgery is warranted.
Collapse
Affiliation(s)
- Alexa Acevedo
- Small Animal Hospital, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
| | - Kirk A Muñoz
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University Columbus, Columbus, OH, USA.
| | - Molly Stec
- College of Veterinary Medicine Michigan State University, East Lansing, MI, USA
| | - Kathryn Pitt
- Wanderlust Veterinary Services LLC, Boulder, CO, USA
| | - Sarah A Jones
- Animal Emergency & Specialty Hospital, Byron Center, MI, USA
| | - Jane M Manfredi
- Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine Michigan State University, East Lansing, MI, USA
| |
Collapse
|
2
|
Ulusan M, Bireller S, Ertugrul B, Kasarci G, Atas MN, Aydemir L, Ergen A, Cakmakoglu B. What if amoxicillin/clavulanic acid reduces the cisplatin anticancer impact on oral cancer treatment? JOURNAL OF STOMATOLOGY, ORAL AND MAXILLOFACIAL SURGERY 2023; 124:101502. [PMID: 37192700 DOI: 10.1016/j.jormas.2023.101502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 05/13/2023] [Indexed: 05/18/2023]
Abstract
Antibiotics-chemotherapeutics combination have become on the table for many cancer treatments. For this reason, we thought that further progress and development of studies to support chemotherapeutic approaches with the use of antibiotics may be beneficial in the clinical field. Cell lines (SCC-15, HTB-41, and MRC-5) were treated with 5-100 μM/ml concentrations of cisplatin (cisp) and amoxicillin/clavulanic acid (amx/cla) with combination (amx/cla-cisp) and alone in three different incubation periods. The all-cells viability was examined with WST-1 and apoptotic activity of the drugs were investigated via cell death ELISA assay kit. The cytotoxic impact of the 100 μM amx/cla-cisp combination was found to be reduced by up to 21.8%, which was significant given that the cytotoxic effect of only cisplatin therapy was 86.1%. Because our findings demonstrated that solo amx/cla therapy have almost no impact on proliferation or death, we focused on the amx/cla-cisp combination effect. It was found that the amx/cla-cisp combination has reduced the apoptotic fragment when comparing with the solely cisp-treated cells. Due to amx/cla-cisp combination on both cells but significantly on SCC-15 recovered the sole cisplatin effect, we believe that there might be a second thought when prescribing antibiotics while treating cancer patients. Not only the antibiotic's type but also the cancer type might interact to lessen the chemotherapeutic agent's impact which is clinically a dilemma to focus on.
Collapse
Affiliation(s)
- Murat Ulusan
- Department of Otolaryngology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Sinem Bireller
- Department of Biochemistry, Faculty of Pharmacy, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey
| | - Baris Ertugrul
- Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Graduate School of Health Sciences, Istanbul University, Istanbul, Turkey
| | - Goksu Kasarci
- Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Graduate School of Health Sciences, Istanbul University, Istanbul, Turkey
| | - Merve Nur Atas
- Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Graduate School of Health Sciences, Istanbul University, Istanbul, Turkey
| | - Levent Aydemir
- Department of Otolaryngology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Arzu Ergen
- Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Bedia Cakmakoglu
- Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
| |
Collapse
|
3
|
He Y, Zheng J, Ye B, Dai Y, Nie K. Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management. Biochem Pharmacol 2023; 216:115787. [PMID: 37666434 DOI: 10.1016/j.bcp.2023.115787] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 08/31/2023] [Accepted: 09/01/2023] [Indexed: 09/06/2023]
Abstract
Chemotherapy is the most common treatment for malignant tumors. However, chemotherapy-induced gastrointestinal toxicity (CIGT) has been a major concern for cancer patients, which reduces their quality of life and leads to treatment intolerance and even cessation. Nevertheless, prevention and treatment for CIGT are challenging, due to the prevalence and complexity of the condition. Chemotherapeutic drugs directly damage gastrointestinal mucosa to induce CIGT, including nausea, vomiting, anorexia, gastrointestinal mucositis, and diarrhea, etc. The pathogenesis of CIGT involves multiple factors, such as gut microbiota disorders, inflammatory responses and abnormal neurotransmitter levels, that synergistically contribute to its occurrence and development. In particular, the dysbiosis of gut microbiota is usually linked to abnormal immune responses that increases inflammatory cytokines' expression, which is a common characteristic of many types of CIGT. Chemotherapy-induced intestinal neurotoxicity is also a vital concern in CIGT. Currently, modern medicine is the dominant treatment of CIGT, however, traditional Chinese medicine (TCM) has attracted interest as a complementary and alternative therapy that can greatly alleviate CIGT. Accordingly, this review aimed to comprehensively summarize the pathogenesis and current management of CIGT using PubMed and Google Scholar databases, and proposed that future research for CIGT should focus on the gut microbiota, intestinal neurotoxicity, and promising TCM therapies, which may help to develop more effective interventions and optimize managements of CIGT.
Collapse
Affiliation(s)
- Yunjing He
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Jingrui Zheng
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Binbin Ye
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Yongzhao Dai
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Ke Nie
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| |
Collapse
|
4
|
Minotti G. All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting. J Pharmacol Exp Ther 2023; 386:111-114. [PMID: 37460159 DOI: 10.1124/jpet.123.001644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 04/03/2023] [Indexed: 07/20/2023] Open
Affiliation(s)
- Giorgio Minotti
- Department of Medicine, Campus Bio-Medico University, and Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
| |
Collapse
|
5
|
Levijoki J, Saloranta L, Tuunainen J, Kaskinoro J, Pappinen S, Nourry S, Betat AM, Maurin A, Pakarinen M, Häkkinen S, Tervapuro J, Pihlasvaara H, Drieu La Rochelle C, Joensuu H. Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting. J Pharmacol Exp Ther 2023; 384:439-444. [PMID: 36635086 DOI: 10.1124/jpet.122.001444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 11/08/2022] [Accepted: 12/19/2022] [Indexed: 01/13/2023] Open
Abstract
Cancer treatments are frequently associated with nausea and vomiting despite greatly improved preventive medication. Administration of antinausea agents as eye drops might provide easy and rapid access to the systemic circulation for prevention of nausea and vomiting and for the treatment of breakthrough nausea, but the ocular administration route has rarely been evaluated. Palonosetron is a second-generation 5-hydroxytryptamine 3 receptor antagonist approved for prevention and treatment of chemotherapy-induced nausea and vomiting. We compared ocular administration of palonosetron to non-active vehicle eye drops and to intravenous palonosetron in the prevention of cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron ocular drops at the dose of 30 µg/kg reduced cumulative nausea over time as measured with the area under the visual analog scale curve by 98% compared with the vehicle and reduced nausea-associated dog behavior by 95%. Vomiting was completely prevented with repeated palonosetron ocular dosing. Hydroxypropyl-β-cyclodextrin (HP-β-CD) palonosetron formulation was well tolerated locally at the palonosetron concentration of 3 mg/ml. Absorption of palonosetron from eye drops was fast. Ten minutes after ocular administration, palonosetron plasma concentrations were similar compared with intravenous administration, and remained similar for six hours. We conclude that palonosetron is rapidly absorbed into the systemic circulation from eye drops. Ocularly administered palonosetron was well tolerated in the HP-β-CD formulation and was highly effective in the prevention of cisplatin-induced nausea and vomiting. Evaluation of the safety and efficacy of ocular administration of palonosetron is warranted in the prevention and treatment of chemotherapy-induced nausea and vomiting in clinical trials. SIGNIFICANCE STATEMENT: Palonosetron, an effective and well-tolerated antiemetic drug was rapidly absorbed into the systemic blood circulation when administered as eye drops. The achieved palonosetron blood concentrations prevented cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron eye drops might provide an easy and quick method for administering palonosetron when parenteral administration is desired and intravenous administration is not feasible.
Collapse
Affiliation(s)
- Jouko Levijoki
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Lasse Saloranta
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Johanna Tuunainen
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Janne Kaskinoro
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Sari Pappinen
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Sandra Nourry
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Anne-Marie Betat
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Anne Maurin
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Maarit Pakarinen
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Sari Häkkinen
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Johanna Tervapuro
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Hertta Pihlasvaara
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Christophe Drieu La Rochelle
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| | - Heikki Joensuu
- Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki University Hospital and University of Helsinki (H.J.)
| |
Collapse
|
6
|
Maitham Abd Ali Mnati, Bahir Abdul Razzaq Mshimesh, Nadia Hamid Mohammed. The Testicular Protection Effect of Thiamine Pyrophosphate Against Cisplatin-treated Male Rats. AL MUSTANSIRIYAH JOURNAL OF PHARMACEUTICAL SCIENCES 2022; 20:147-155. [DOI: 10.32947/ajps.v20i4.784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
Abstract
Infertility is a worldwide problem affecting both genders, it can be defined as the inability of the adult males to make a fertile woman pregnant after one year of regular intercourse. Cisplatin considers one of the most potent antineoplastic drugs that is extensively
used, alone or in combination with other antitumor agents, to manage solid and germ cell cancer. The major drawback in cisplatin treatment is its damaging consequence on various body tissue, including the testis, liver, renal and others. One of its pronounced adverse effects is testicular injury, which may proceed to end with infertility. Thiamine pyrophosphate is the active form of thiamine which has an important role in the oxidative phosphorylation pathway. It acts as a co-factor and energy source for many cellular enzymes, also it utilizes by pentose-phosphate shut that elevates NADPH and improves antioxidants level. This study aimed to evaluate the effect of thiamine pyrophosphate on sperm parameters and gonadotropic hormones (luteal and follicle-stimulating hormone) of male rats exposed to a single dose of cisplatin.
Twenty-eight albino male rats were randomly grouped into four groups. Control group: received normal saline, Cisplatin group: received normal saline and cisplatin, TPP50 group: received thiamine pyrophosphate (50mg/kg) with cisplatin, and TPP100 group: as third group (TPP50) but thiamine pyrophosphate dose was 100 mg/kg. Semen samples used to measure the sperms viability and morphology, while serum samples were gathered to measure the levels of gonadotropic hormones (FSH and LH).
This study revealed that rat’s testicular function was notably deteriorated by cisplatin administration, represented by a reduction in sperm parameters (viability and normal morphology), and serum gonadotropic hormones (FSH and LH). In this work, thiamine pyrophosphate was act as a protective agent that ameliorates rat’s testicular damage induced by cisplatin in a dose-dependent manner. The suggested mechanism may attribute to its antioxidant and anti-apoptotic action
Collapse
|
7
|
Aoyama M, Shioya M, Tsukamoto Y, Hasegawa H, Sugita S. The effects of cisplatin, an emetic agent, on behavior and plasma cortisol levels in goats. Anim Sci J 2021; 92:e13607. [PMID: 34318567 PMCID: PMC9286031 DOI: 10.1111/asj.13607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 06/20/2021] [Accepted: 06/24/2021] [Indexed: 12/01/2022]
Abstract
Ruminants are not considered to experience nausea because they do not possess the emetic reflex. This study examined the effects of administration of cisplatin (cis‐diamminedichloro platinum (II): CDDP), a common emetic agent, on the behavior of goats. In Experiment 1, adult Shiba goats received intravenous (IV) administration of CDDP. CDDP‐administered goats spent a shorter time feeding (P < 0.01), lied down earlier (P < 0.01), and spent a longer period lying down (P < 0.01) than the saline‐administered control goats, and sometimes, they directed their face downward and close their eyes. These behavioral responses were followed by a significant (P < 0.01) increase in plasma cortisol (Cor) levels, which indicated that goats experienced stress. The dose dependency was found in the extent of the CDDP effects. In Experiment 2, the effects of pretreatment of ondansetron (Ond), an antiemetic agent, were examined. Pretreatment of Ond extended the latency of lying (P < 0.01), shortened the time spent lying (P < 0.05), and reduced the extent of the increase in plasma Cor levels (P < 0.01). These results suggested that CDDP administration generated some state of stress in goats via the similar physiological mechanisms as emesis‐caused stress in emetic species.
Collapse
Affiliation(s)
- Masato Aoyama
- Department of Animal Science, School of Agriculture, Utsunomiya University, Utsunomiya-shi, Japan
| | - Minami Shioya
- Department of Animal Science, School of Agriculture, Utsunomiya University, Utsunomiya-shi, Japan
| | - Yume Tsukamoto
- Department of Animal Science, School of Agriculture, Utsunomiya University, Utsunomiya-shi, Japan
| | - Hitomi Hasegawa
- Department of Animal Science, School of Agriculture, Utsunomiya University, Utsunomiya-shi, Japan
| | - Shoei Sugita
- Department of Animal Science, School of Agriculture, Utsunomiya University, Utsunomiya-shi, Japan
| |
Collapse
|
8
|
Activation of the hypothalamic-pituitary-adrenal axis by exogenous and endogenous GDF15. Proc Natl Acad Sci U S A 2021; 118:2106868118. [PMID: 34187898 PMCID: PMC8271778 DOI: 10.1073/pnas.2106868118] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
An acute increase in the circulating concentration of glucocorticoid hormones is essential for the survival of severe somatic stresses. Circulating concentrations of GDF15, a hormone that acts in the brain to reduce food intake, are frequently elevated in stressful states. We now report that GDF15 potently activates the hypothalamic-pituitary-adrenal (HPA) axis in mice and rats. A blocking antibody to the GDNF-family receptor α-like receptor completely prevented the corticosterone response to GDF15 administration. In wild-type mice exposed to a range of stressful stimuli, circulating levels of both corticosterone and GDF15 rose acutely. In the case of Escherichia coli or lipopolysaccharide injections, the vigorous proinflammatory cytokine response elicited was sufficient to produce a near-maximal HPA response, regardless of the presence or absence of GDF15. In contrast, the activation of the HPA axis seen in wild-type mice in response to the administration of genotoxic or endoplasmic reticulum toxins, which do not provoke a marked rise in cytokines, was absent in Gdf15 -/- mice. In conclusion, consistent with its proposed role as a sentinel hormone, endogenous GDF15 is required for the activation of the protective HPA response to toxins that do not induce a substantial cytokine response. In the context of efforts to develop GDF15 as an antiobesity therapeutic, these findings identify a biomarker of target engagement and a previously unrecognized pharmacodynamic effect, which will require monitoring in human studies.
Collapse
|
9
|
Kantyka ME, Meira C, Bettschart-Wolfensberger R, Hartnack S, Kutter APN. Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis. J Vet Emerg Crit Care (San Antonio) 2020; 30:436-441. [PMID: 32515910 DOI: 10.1111/vec.12954] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 09/07/2018] [Accepted: 09/19/2018] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To evaluate the incidence of tranexamic acid (TXA)-induced nausea and vomiting after the prophylactic use of 2 antiemetics, ondansetron and maropitant, compared with saline. DESIGN Prospective, blinded, placebo-controlled, randomized, crossover study. SETTING University research facility. ANIMALS Eight adult, purpose-bred Beagles. INTERVENTION Dogs received 3 treatments on 3 occasions with a 3-week washout period. Either maropitant (1 mg/kg), ondansetron (0.2 mg/kg), or saline solution was given intravenously in equal volumes, followed 10 minutes later by 50 mg/kg IV TXA. A blinded observer evaluated the dogs for signs of vomiting and nausea for 30 minutes. The severity of nausea was assessed with a visual analog scale (VAS) and recorded at baseline before TXA, and at the end of 3 observational periods: 0-5, 5-15, and 15-30 minutes after TXA. A generalized linear mixed effect model was used to assess for group and period effects. Statistical significance was set at P < 0.05 . MEASUREMENTS AND MAIN RESULTS None of the dogs vomited after maropitant. Emesis occurred in 5 out of 8 dogs (62.5%), a median (range) of 1 time (1-2) after ondansetron and 1 time (1-3) after saline. There was a significant effect on vomiting of maropitant against saline (P < 0.0001) but not for ondansetron against saline (P = 0.53). The highest nausea VASs were recorded during the first 5 minutes after TXA with a significant reduction of VAS variability in the maropitant group (P = 0.003). The effect of maropitant and ondansetron against saline on the severity of nausea was not statistically significant (P = 0.069). CONCLUSION The neurokinin 1 receptor antagonist maropitant at the dose used, administered IV 10 minutes before 50 mg/kg TXA, was effective in preventing vomiting compared with ondansetron and placebo. Our results support the prophylactic IV administration of maropitant in dogs that are scheduled to receive TXA.
Collapse
Affiliation(s)
- Marta E Kantyka
- Section of Anesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty of the University of Zurich, Zurich, Switzerland
| | - Carolina Meira
- Section of Anesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty of the University of Zurich, Zurich, Switzerland
| | - Regula Bettschart-Wolfensberger
- Section of Anesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty of the University of Zurich, Zurich, Switzerland
| | - Sonja Hartnack
- Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Annette P N Kutter
- Section of Anesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty of the University of Zurich, Zurich, Switzerland
| |
Collapse
|
10
|
Kenward H, Elliott J, Lee T, Pelligand L. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Vet Res 2017; 13:244. [PMID: 28814338 PMCID: PMC5559813 DOI: 10.1186/s12917-017-1156-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 08/03/2017] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Nausea is a subjective sensation which is difficult to measure in non-verbal species. The aims of this study were to determine the efficacy of three classes of antiemetic drugs in a novel low dose cisplatin model of nausea and vomiting and measure change in potential nausea biomarkers arginine vasopressin (AVP) and cortisol. A four period cross-over blinded study was conducted in eight healthy beagle dogs of both genders. Dogs were administered 18 mg/m2 cisplatin intravenously, followed 45 min later by a 15 min infusion of either placebo (saline) or antiemetic treatment with ondansetron (0.5 mg/kg; 5-HT3 antagonist), maropitant (1 mg/kg; NK1 antagonist) or metoclopramide (0.5 mg/kg; D2 antagonist). The number of vomits and nausea associated behaviours, scored on a visual analogue scale, were recorded every 15 min for 8 h following cisplatin administration. Plasma samples were collected to measure AVP, cortisol and antiemetic drug concentrations. RESULTS The placebo treated group vomited an average number of 7 times (range 2-13). None of the dogs in either the ondansetron or maropitant treated groups vomited during the observation period. The onset of nausea-like behaviour in the placebo-treated group occurred at t3.5h and peaked at t4.75h with nausea behaviour score of 58.5 ± 4.6 mm. Ondansetron and maropitant reduced overall the area under the curve of nausea behaviour score by 90% and 25%, respectively. Metoclopramide had no effect on either vomiting or nausea. Cisplatin-induced nausea and vomiting caused concomitant increases in AVP and cortisol. In the placebo-treated group, AVP and cortisol increased from t2.5h, peaked at t5h (11.3 ± 2.9 pmol L-1 and 334.0 ± 46.7 nmol/L, respectively) and returned to baseline by t8h. AVP and cortisol increases were completely prevented by ondansetron and only partially by maropitant, while metoclopramide had no effect. The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively. CONCLUSIONS 5-HT3 receptor antagonist ondansetron demonstrates the greatest anti-emetic and anti-nausea efficacy of the three drugs. AVP and cortisol appear to be selective biomarkers of nausea rather than emesis, providing a means of objectively measuring of nausea in the dog.
Collapse
Affiliation(s)
- Hannah Kenward
- Department of Comparative Biomedical Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK
| | - Jonathan Elliott
- Department of Comparative Biomedical Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK
| | - Terry Lee
- Analytical Services International (ASI), St Georges, University of London, Cranmer Terrace, London, SW17 0RE, UK
| | - Ludovic Pelligand
- Department of Comparative Biomedical Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK. .,Department of Clinical Sciences and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK.
| |
Collapse
|
11
|
Zhou ZZ, Cheng YF, Zou ZQ, Ge BC, Yu H, Huang C, Wang HT, Yang XM, Xu JP. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses. ACS Chem Neurosci 2017; 8:135-146. [PMID: 27690383 DOI: 10.1021/acschemneuro.6b00271] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Depression involving neuroinflammation is one of the most common disabling and life-threatening psychiatric disorders. Phosphodiesterase 4 (PDE4) inhibitors produce potent antidepressant-like and cognition-enhancing effects. However, their clinical utility is limited by their major side effect of emesis. To obtain more selective PDE4 inhibitors with antidepressant and anti-neuroinflammation potential and less emesis, we designed and synthesized a series of N-alkyl catecholamides by modifying the 4-methoxybenzyl group of our hit compound, FCPE07, with an alkyl side chain. Among these compounds, 10 compounds displayed submicromolar IC50 values in the mid- to low-nanomolar range. Moreover, 4-difluoromethoxybenzamides 10g and 10j, bearing isopropyl groups, exhibited the highest PDE4 inhibitory activities, with IC50 values in the low-nanomolar range and with higher selectivities for PDE4 (approximately 5000-fold and 2100-fold over other PDEs, respectively). Furthermore, compound 10j displayed anti-neuroinflammation potential, promising antidepressant-like effects, and a zero incidence rate of emesis at 0.8 mg/kg within 180 min.
Collapse
Affiliation(s)
- Zhong-Zhen Zhou
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Yu-Fang Cheng
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Zheng-Qiang Zou
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Bing-Chen Ge
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Hui Yu
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Cang Huang
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Hai-Tao Wang
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Xue-Mei Yang
- Hygiene
Detection Center, School of Public Health, Southern Medical University, Guangzhou 510515, China
| | - Jiang-Ping Xu
- Department of Neuropharmacology and Novel
Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
12
|
McDuffie JE, Chen Y, Ma JY, Lee S, Lynch KM, Hamlin DM, Nguyen L, Rizzolio M, Sonee M, Snook S. Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine. Toxicol Res (Camb) 2016; 5:1202-1215. [PMID: 30090426 DOI: 10.1039/c5tx00497g] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 05/19/2016] [Indexed: 11/21/2022] Open
Abstract
This 10-day (D) study was conducted to evaluate changes in traditional and newer kidney safety biomarker expression levels in dogs. Animals received cisplatin (CDDP, 0.75 mg per kg per day) or 0.9% Saline (vehicle) for 5 days. Serum/urine samples were collected at various time points. Cage-side observations included emesis (D1-2/D4-D5/D7-9), absence of stool (D5-9/D11), soft stool (D4-7/D12), excessive salivation (D1/D3/D5-6), decreased food consumption (D5-8), decreased activity (D7-8) and/or dehydration (D7). Animals were necropsied when serum creatinine (sCr) levels measured at ≥1.9 mg dL-1, indicating significant loss of renal function; or at the end of the study (D11). When compared to controls, increases in BUN/sCr were detected on D3, D5 and/or D8. Increases in urinary total protein (Ur TP) were noted on D6. The moribund dog that was euthanized early on D7 showed insignificant increases in urinary osteopontin (Ur OPN), urinary neutrophil gelatinase-associated lipocalin (Ur NGAL), urinary clusterin (Ur CLU), sCr, serum cystatin C (sCYS C) and urinary cystatin C (Ur CYS C) on D5 when compared to controls. Insignificant increases in urinary albumin (Ur ALB) were observed from an animal that was euthanized on D7 and 1 : 2 surviving animals on D8 relative to baseline. From three dogs that were euthanized on D9, increases in Ur CLU, and/or sCYS C were noted on D8 relative to baseline. The two surviving dogs showed elevated Ur CLU and 1 : 2 surviving dogs showed elevated Ur CYS C. Decreased urinary kidney injury molecule 1 (Ur KIM-1) on D3/D5 was evident (versus baseline and controls). CDDP-induced cortico-medullary lesions were characterized as minimal to mild tubule degeneration/necrosis, dilatation, regeneration, cell alteration, intratubular casts, interstitial inflammation and vacuolization. Increased Ur OPN and Ur CLU correlated with enhanced OPN and CLU immunopositive staining in damaged cortical epithelium in the proximal tubules. Enhanced KIM-1 staining in damaged cortico-medullary tubular epithelium appeared in the absence of rises in Ur KIM-1. This study showed changes in kidney safety protein biomarkers associated with CDDP nephrotoxicity in dogs and possibly in humans.
Collapse
Affiliation(s)
- J E McDuffie
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - Y Chen
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - J Y Ma
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - S Lee
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - K M Lynch
- Department of Safety Assessment , GlaxoSmithKline , King of Prussia , PA , USA
| | - D M Hamlin
- Investigative Toxicology , Eli Lilly & Co. , Indianapolis , IN , USA
| | - L Nguyen
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - M Rizzolio
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - M Sonee
- Discovery Sciences , Janssen Research & Development , L.L.C. , Spring House , PA , USA
| | - S Snook
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| |
Collapse
|